{(S)-6-[4-((R)-3-fluoro-pyrrolidin-1-yl)-benzenesulfonylamino]-1,2,3,4-tetrahydro-naphthalen-2-yl}-propyl-carbamic acid tert-butylester | 884307-14-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: {(S)-6-[4-((R)-3-fluoro-pyrrolidin-1-yl)-benzenesulfonylamino]-1,2,3,4-tetrahydro-naphthalen-2-yl}-propyl-carbamic acid tert-butylester
• 英文别名: {(S)-6-[4-((R)-3-fluoro-pyrrolidin-1-yl)benzenesulfonylamino]-1,2,3,4-tetrahydro-naphthalen-2-yl}-propyl-carbamic acid tert-butyl ester；tert-butyl N-[(2S)-6-[[4-[(3R)-3-fluoropyrrolidin-1-yl]phenyl]sulfonylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]-N-propylcarbamate
• CAS: 884307-14-6
• 化学式: C₂₈H₃₈FN₃O₄S
• 分子量: 531.692
• InChiKey: MIAJLJQKFKUYTJ-RDGATRHJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  [(S)-6-(4-bromo-benzenesulfonylamino)-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-carbamic acid tert-butyl ester 、 3(R)-氟吡咯烷 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以47%的产率得到{(S)-6-[4-((R)-3-fluoro-pyrrolidin-1-yl)-benzenesulfonylamino]-1,2,3,4-tetrahydro-naphthalen-2-yl}-propyl-carbamic acid tert-butylester
  参考文献：
  名称：

  [EN] ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR
  [FR] COMPOSES AROMATIQUES D'ARYLSULFONYLMETHYLE OU D'ARYLSULFONAMIDE SUBSTITUES PERMETTANT DE TRAITER DES TROUBLES REPONDANT A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE

  摘要：

  本发明涉及式(I)的芳香族化合物，其中Ar是苯基或芳香族5-或6-成员C-键合杂芳基，其中Ar可以携带1个基团Ra，Ar也可以携带1个或2个基团Rb；X是N或CH；Y是O、S、-CH=N-、-CH=CH-或-N=CH-；A是CH2i、O或S；E是CR6R7或NR3；R1是C1-C4-烷基、C3-C4-环烷基、C3-C4-环烷基甲基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-环烷基甲基、氟代C3-C4-烯基、甲酰基或C,-C3-烷基羰基；R1a是H、C2-C4-烷基、C3-C4-环烷基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基，或R1a和R2一起是(CH2)n，其中n为2或3，或R1a和R2a一起是(CH2)n，其中n为2或3；R2和R2a彼此独立地是H、CH3、CH2F、CHF2或CF3；R3是H或C1-C4-烷基；R6、R7彼此独立地选自H、C1-C2-烷基和氟代C1-C2-烷基；以及其生理耐受的酸盐。该发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗对多巴胺D3受体配体敏感的医疗疾病的药物组合物。

  公开号：

  WO2006040178A1

文献信息

• Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor
  申请人：Drescher Karla

  公开号：US20090012074A1

  公开（公告）日：2009-01-08

  The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; Y is O, S, —CH═N—, —CH═CH— or —N═CH—; A is CH 2 , O or S; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 2 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, or R 1a and R 2 together are (CH 2 ) n with n being 2 or 3, or R 1a and R 2a together are (CH 2 ) n with n being 2 or 3; R 2 and R 2a are independently of each other H, CH 3 , CH 2 F, CHF 2 or CF 3 ; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, C 1 -C 2 -alkyl and fluorinated C 1 -C 2 -alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及公式I的芳香族化合物，其中Ar是苯基或含有5或6个成员的芳香族C-连接杂环基团，其中Ar可以携带1个基团Ra，也可以携带1或2个基团Rb；X是N或CH；Y是O，S，-CH═N-，-CH═CH-或-N═CH-；A是CH2，O或S；E是CR6R7或NR3；R1是C1-C4烷基，C3-C4环烷基，C3-C4环烷基甲基，C3-C4烯基，氟代C1-C4烷基，氟代C3-C4环烷基，氟代C3-C4环烷基甲基，氟代C3-C4烯基，甲酰基或C1-C3烷基羰基；R1a是H，C2-C4烷基，C3-C4环烷基，C3-C4烯基，氟代C1-C4烷基，氟代C3-C4环烷基，或R1a和R2一起是( )n，其中n为2或3，或R1a和R2a一起是( )n，其中n为2或3；R2和R2a相互独立地是H，CH3， F，CHF2或CF3；R3是H或C1-C4烷基；R6，R7相互独立地选择自H，C1-C2烷基和氟代C1-C2烷基；以及其生理耐受酸盐。本发明还涉及使用公式I的化合物或其药学上可接受的盐制备用于治疗可通过多巴胺D3受体配体治疗的医疗障碍的制药组合物的用途。
• Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
  申请人：Drescher Karla

  公开号：US08969552B2

  公开（公告）日：2015-03-03

  The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; Y is O, S, —CH═N—, —CH═CH— or —N═CH—; A is CH2, O or S; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, or R1a and R2 together are (CH2)n with n being 2 or 3, or R1a and R2a together are (CH2)n with n being 2 or 3; R2 and R2a are independently of each other H, CH3, CH2F, CHF2 or CF3; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, C1-C2-alkyl and fluorinated C1-C2-alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及式I的芳香族化合物，其中Ar是苯基或芳香5-或6-成员C-键杂环基，其中Ar可以携带1个基团Ra，其中Ar还可以携带1或2个基团Rb; X是N或CH; Y是O，S，-CH═N-，-CH═CH-或-N═CH-; A是CH2，O或S; E是CR6R7或NR3; R1是C1-C4-烷基，C3-C4-环烷基，C3-C4-环烷基甲基，C3-C4-烯基，氟化C1-C4-烷基，氟化C3-C4-环烷基，氟化C3-C4-环烷基甲基，氟化C3-C4-烯基，甲酰基或C1-C3-烷基羰基; R1a是H，C2-C4-烷基，C3-C4-环烷基，C3-C4-烯基，氟化C1-C4-烷基，氟化C3-C4-环烷基，或R1a和R2一起是( )n，其中n为2或3，或R1a和R2a一起是( )n，其中n为2或3; R2和R2a彼此独立地为H，CH3， F，CHF2或CF3; R3为H或C1-C4-烷基; R6，R7彼此独立地选自H，C1-C2-烷基和氟化C1-C2-烷基;及其生理耐受的酸加成盐。本发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易受多巴胺D3受体配体治疗的医疗障碍的制药组合物。
• US8969552B2
  申请人：——

  公开号：US8969552B2

  公开（公告）日：2015-03-03